Establishment of minimal positive-control conditions to ensure brain safety during rapid development of emergency vaccines
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Baek, Hyekyung | - |
dc.contributor.author | Kim, Kwang Ho | - |
dc.contributor.author | Park, Min Young | - |
dc.contributor.author | Kim, Kyeongryun | - |
dc.contributor.author | Ko, Bokyeong | - |
dc.contributor.author | Seo, Hyung Seok | - |
dc.contributor.author | Kim, Byoung Soo | - |
dc.contributor.author | Hahn, Tae-Wook | - |
dc.contributor.author | Yi, Sun Shin | - |
dc.date.accessioned | 2021-08-11T16:24:26Z | - |
dc.date.available | 2021-08-11T16:24:26Z | - |
dc.date.issued | 2017 | - |
dc.identifier.issn | 1229-845X | - |
dc.identifier.issn | 1976-555X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/8429 | - |
dc.description.abstract | With the increase in international human and material exchanges, contagious and infectious epidemics are occurring. One of the effective methods of epidemic inhibition is the rapid development and supply of vaccines. Considering the safety of the brain during vaccine development is very important. However, manuals for brain safety assays for new vaccines are not uniform or effective globally. Therefore, the aim of this study is to establish a positive-control protocol for an effective brain safety test to enhance rapid vaccine development. The blood-brain barrier's tight junctions provide selective defense of the brain; however, it is possible to destroy these important microstructures by administering lipopolysaccharides (LPSs),thereby artificially increasing the permeability of brain parenchyma. In this study, test conditions are established so that the degree of brain penetration or brain destruction of newly developed vaccines can be quantitatively identified. The most effective conditions were suggested by measuring time-dependent expressions of tight junction biomarkers (zonula occludens-1 [ZO-1] and occludin) in two types of mice (C57BL/6 and ICR) following exposure to two types of LPS (Salmonella and Escherichia). In the future, we hope that use of the developed positive-control protocol will help speed up the determination of brain safety of novel vaccines. | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한수의학회 | - |
dc.title | Establishment of minimal positive-control conditions to ensure brain safety during rapid development of emergency vaccines | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.4142/jvs.2017.18.S1.371 | - |
dc.identifier.scopusid | 2-s2.0-85027999382 | - |
dc.identifier.wosid | 000408327300014 | - |
dc.identifier.bibliographicCitation | Journal of Veterinary Science, v.18, pp 371 - 379 | - |
dc.citation.title | Journal of Veterinary Science | - |
dc.citation.volume | 18 | - |
dc.citation.startPage | 371 | - |
dc.citation.endPage | 379 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002251502 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Veterinary Sciences | - |
dc.relation.journalWebOfScienceCategory | Veterinary Sciences | - |
dc.subject.keywordPlus | TIGHT JUNCTION | - |
dc.subject.keywordPlus | BARRIER | - |
dc.subject.keywordPlus | OCCLUDIN | - |
dc.subject.keywordPlus | PERMEABILITY | - |
dc.subject.keywordPlus | PROTEIN | - |
dc.subject.keywordAuthor | blood-brain barrier | - |
dc.subject.keywordAuthor | lipopolysaccharides | - |
dc.subject.keywordAuthor | positive-protocol | - |
dc.subject.keywordAuthor | tight junctions | - |
dc.subject.keywordAuthor | vaccine | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.